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Circulating lgA Immune Complexes in Patients with Psoriasis 
RussELL P. HALL, M .D., GARY L. PECK, M .D., AND THOMAS J. LAWLEY, M .D. 
Dermatology Branch., Nat ional Cancer ln.stitule, National ln.~titules of Heal/h., Belh.e.~da, Maryland, U.S.A. 
The sera of 21 patients with psoriasis were examined 
for the presence of IgA-containing circulating immune 
complexes (CIC) using the Raji IgA radioimmunoassay. 
In addition, the Raji IgG radioimmunoassay and 1251-elq 
binding assay were used to detect IgG- and IgM-contain-
ing CIC. Twenty-five patients with other hyperkeratotic 
skin disorders were studied as controls. Patients were 
studied before institution of systemic therapy with etre-
tinate (20 patients) or 13-cis-retinoic acid (1 patient). In 
addition, sera of15 of the patients treated with etretinate 
were studied before, during, and after therapy. The ex-
tent of pretreatment disease involvement as well as re-
sponse to therapy were evaluated in a blinded fashion. 
Fourteen of21 (67%) patients with psoriasis had evidence 
of IgA-containing CIC at some time during the course of 
their disease, as compared to only 1 of 25 patients with 
other hyperkeratotic skin disorders. In contrast, only 2 
of 19 (11%) had evidence oflgG-containing CIC using the 
Raji IgG assay, and only 1 of 19 (5%) had evidence oflgG-
or IgM-containing CIC using the 125I-Clq binding assay. 
A positive correlation was found between the extent of 
pretreatment disease involvement and the level of IgA-
containing CIC by linear regression analysis (p = 0.01). 
There was, however, no correlation between clinical im-
provement and the presence or level of IgA-containing 
CIC in 15 patients followed during therapy. Sucrose 
density gradient analysis of the IgA-containing eie 
found in2 of these patients demonstrated IgA-containing 
CIC in the 9S to 138 region. The finding oflgA-containing 
CIC in a significant number of patients with psoriasis 
and the relative absence of IgG- or IgM-containing ere 
suggest that IgA-containing CIC may play a role in pso-
riasis. The lack of correlation with clinical improvement, 
however, suggests these IgA-containing CIC are not di-
rectly related to the cutaneous manifestations of pso-
riasis, but may be important in the modulation of im-
mune or inflammatory responses in these patients. 
Several recent r eports have indicated that abnormali t ies of 
t he immune system exis t in patients with psoriasis. These 
patients have been found to have abnormal skin test reactions 
[1], as well as impair ed responses to a variety of lymphocyte 
mi to gens [ 1 ], abnormal suppressor T -cell function [2] , abnormal 
monocyte function [3], and abnorma l ne utrophil chemotaxis 
[ 4). In addition, abnorma lities of t he humora l immune system 
have also been reported. Serum immunoglobulins, ma inly lgA, 
have been found to be elevated [5], a nd circulating immune 
complexes (ere) have bee n detected in the sera of some patients 
with psoriasis (6-8]. These ere, howeve r, have not been de-
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tected in all patients with psoriasis [9]. Previous ly the assays 
used to detect ere in these patie nts ha ve been able to detect 
only rgG- or rgM-containing ere. S ince abnormalities of serum 
a nd salivary IgA have been re porte d in patients with psorias is 
it seemed possible that rgA-containing ere could be present in 
t he sera of t hese patients. 
We have d eveloped a sensitive radioimmunoassay for the 
detection of rgA-containing ere utilizing t he Raji cell and in 
preliminaTy studies found t h at a number of psoriatic patients 
had IgA-containing e re (10]. In order to examine the re lation-
s hip of t hese rgA-containing ere to th e pathogenes is of pso-
riasis, we have studied the sera of 21 patients with psoriasis for 
lgA-con taining ere be fore, during, a nd a fter therapy with 
synthetic retinoids. In addition, we h a ve examined the sera of 
these patie nts for IgG-conta ining ere using the Raji cell IgG 
radioimmunoassay, a nd for IgG- or IgM -conta ining ere using 
t he 1 ~''I-elq binding assay ( 1 ~"r-eiqBA). 
MATERIALS AND METHODS 
Patients 
Twenty-one patients with psoriasis (16 male, 5 female, mean age= 
41 years) were studied. The diagnosis of psoriasis was established by 
the typical clinical appearance. Nineteen patients had large plaque type 
psoriasis, while 2 had erythrodermic psoria is. None of the patients had 
psoriatic arthritis or pustular psoriasis. 
Sera of 20 of these patients were obtained prior to institut ion of 
systemic therapy with etretinate (Ro 10-9359) (Hoffmann-La Hoche 
Inc., Nutley, New J ersey) a t a dosage of 0.25-1.0 mg/ kg per dt~y. All 
topical and other systemic medications had been discontinued fur a t. 
least I month. The pretreatment disease activi ty, expressed as percent 
of total body involvement, was assessed in a blinded fashion, as was the 
degree of change during therapy (0 = no change, l + to 5+ = improve-
ment, -1 to -2 = worsening). Of this group of 20 patients, 15 were 
followed with serial serum samples for at least 16 weeks during therapy 
wi th etretinate. The additional patient was studied prior to and after 
systemic therapy with 13-cis- re tinoic acid. 
The sera of 25 patients with other hyperkeratotic skin diseases were 
used as controls (7 pityriasis rubra pilaris, 6 lamellar ichthyosis. 1 
erythrokeratoderma variabilis, 3 nonbullous congeni ta l ichthyos iform 
erythroderma, 3 keratosis follicularis, 4 epidermolytic hyperkeratosis, 
.I parakeratosis) . Sera from 23 normal volunteers in the Clinical Center 
were used for determination of normal va lues. 
Ra.ji Cell Assays 
The Raj i cell assay for lgG-coni.a ining CIC was modified from thai 
of Theofilopoulos et. a l (11-.1 3]. The Raji ce ll IgA immune complex 
assay was performed as previously described [ IOl 
An upper 95% confidence limi t (U;) is obtained daily using a panel of 
control serum samples. The mean value of a duplica te analysis of the 
test serum (1';) is divided by U,. If this ra tio (T;/U,) is greater than 1, 
the test serum value has exceeded the upper 95% confidence limi t, and 
is judged abnormal. 
' ~'' I- Ciq Binding Assay 
The ' ~'' l -C lq binding assay was performed as described previously 
[ 14). The upper 95% confidence limit of Clq binding activity (ClqBA ) 
in normal human serum was determined to be 10%. 
C3 and lgA Determinations 
Serum C3 and lgA levels were quantitated using commercia lly avai l-
able rad ial immunodiffusion plates (Behring Diagnostics). 
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Density-Gradient Ultracentrifugation 
The sedimentation chamcteristics of the lgA-containing CIC de-
tected in the sera of 2 patients with psoriasis were determined using 
density gradient ultracentrifugation. This was performed by layering 
0.25 ml of serum diluted 1:4 in phosphate-buffered saline, pH 7.4, over 
a 10-40% continuous sucrose density gradient in 6-ml Beckman cellu-
lose nitrate tubes (Beckman Instruments, Mountainside, New Jersey). 
The gradients were then centrifuged at 178,000 g for 17.5 hat 4 °C in an 
L2-65B Beckman ultracentrifuge equipped with an SW65 rotor. Eleven 
fractions were collected from the bottom and were tes ted for lgA-
containing CIC, using the Raji cell lgA radioimmunoassay. 
RESULTS 
Immune Complex Assays 
Nine of 20 (45%) patients studied before etretinate therapy 
had evidence of IgA-containing CIC. The mean positive value 
(mean fractional increase over upper 95% confidence limit, T;/ 
U;) was L26. The patient treated with 13-cis-retinoic acid did 
not have IgA-containing CIC (T;/U; = 0.65). In contrast, only 
2 of 19 (11 %) patients had evidence oflgG-containing CIC using 
the Raji cell IgG radioimmunoassay (T;/U; = L7, L1), and only 
1 of 19 (5%) had evidence of IgG- or IgM-containing CIC using 
the 125I-ClqBA (% ClqBA = 12.5%) (p < .025 Fisher Exact Test) 
(Fig 1). 
Only 1 of 25 patients with other skin diseases was found to 
have IgA-containing CIC (pityrasis ruba pilaris, T;/U; = 1.17). 
Correlation of IgA Immune Complex Levels and Disease 
Severity 
Prior to the institution of therapy 5 of the 21 patients studied 
had 10% or less total body surface involvement with psoriasis, 
9 had 10-50% involvement, 5 had 50-90% involvement, and 2 
patients had greater than 90% total body surface involved. 
There was a positive correlation between the extent of pretreat-
ment body surface involvement and the level of IgA-containing 
CIC as determined by linear regression analysis (p = 0.01) (Fig 
2). 
Serial Stuiiies of IgA-Containing Immune Complexes During 
Therapy with Etretinate 
Fifteen of the 20 patients evaluated prior to institution of 
therapy were followed with multiple serum samples for at least 
16 weeks during treatment with etretinate. All patients showed 
clinical improvement (mean improvement = +3.4, range +2 to 
+5) . No correlation between clinical improvement and presence 
or level of IgA-containing CIC was noted during therapy. In-
deed, when paired sample analysis of each patient was done 
using pre- and posttreatment values of IgA-containing CIC, no 
significant change was noted (p = 0.13). Five of these 15 
patients were found to have IgA-containing CIC prior to the 
institution of therapy. During therapy 3 of the 5 patients 
reverted to normal. In contrast, however, 6 of the 10 patients 
Raji lgA 
(21) 
FIG 1. Pretreatment circulating immune complex levels in patients 
with psoriasis using t he Raji lgA, Raji lgG, and 12"1-Ciq binding radioim-
munoassays. Cross-hatched areas represent normal range in each 
assay. 
Vol. 80, No. 6 
1.6 
• • • 1.4 
• 
1.2 






r = .535 
p = .012 
• 
< 10 1Q-50 5Q-90 > 90 
% Body Surface Involvement 
FIG 2. Levels of lgA-containing circulating immune complexes vs. 
the pretreatment percent of total body involvement in 21 patients with 
psoriasis. Solid line represents linear regression analysis of the data. 
who initially did not have IgA-containing CIC, did develop IgA-
containing CIC transiently during therapy despite clinical im-
provement. Overall, 14 of the 21 (67%) patients studied had 
evidence of IgA-containing CIC at some time during the course 
of their disease. 
Serum IgA and C3 Levels 
Serum IgA and C3 levels were measured in 18 patients. Three 
of 18 patients were found to have elevated serum IgA levels 
(normal range, 90-450 mg/dl). There was, however, no corre-
lation between serum IgA level and the presence or level of 
IgA-containing CIC. Only 1 of 18 patients had slightly abnormal 
serum C3 level (46 mg/dl; normal range, 50-120 mg/dl). 
Density Gradient Ultracentrifugation 
Sucrose density gradient ultracentrifugation was performed 
on serum samples from 2 psoriasis patients with IgA-containing 
CIC. Using the Raji cell IgA radioimmunoassay, IgA-containing 
CIC were found to sediment predominantly in the 9S to 13S 
region. 
DISCUSSION 
Circulating IgG- or IgM-containing immune complexes have 
been detected in a variable percentage of patients with psoriasis, 
however their lack of conelation with disease activity makes 
the significance of these findings difficult to determine [6,8,9]. 
We have developed a radioimmunoassay for rgA-containing 
CIC and preliminary investigation indicated that nearly half of 
randomly selected sera from patients with psoriasis had IgA-
containing ere [10). Since patients with psoriasis have been 
found to have abnormalities of both serum and secretory IgA 
[5], and since a variety of gastrointestinal abnormalities have 
also been reported in some patients with psoriasis [15,16), it 
seemed possible that rgA-containing ere could play a role in 
the pathogenesis of psoriasis. 
We have found that 14 of 21 (67%) patients with psoriasis 
had rgA-containing ere present at some time during their 
clinical course. This is in marked contrast to the findings in 
patients with other hyperkeratotic skin diseases, where only 1 
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of 25 patients had evidence of lgA-containing CIC. Of 21 pa-
tients studied who had been off all medication for 1 month prior 
to retinoid therapy, 9 (43%) had l gA-containing CIC. In addi-
tion, a correlation was found between the pretreatment skin 
disease severity, expressed as percent of total body involvement, 
and the level of lgA-containing CIC. The biologic significance 
of this finding is, however, unclear, due to the relatively small 
number of patients with more severe involvement. In addition, 
when 15 patients were followed with serial serum samples, no 
correlation was found between clinical improvement and the 
presence or level of lgA-containing CIC. Indeed, 6 of the 10 
patients with no lgA-containing CIC detected before treatment 
developed transient lgA-containing CIC while on treatment. In 
contrast, IgG- or IgM-containing CIC were rarely detected 
utilizing either the 1251-ClqBA or the Raji cell lgG radioimmu-
noassay, and no correlation was found between disease activity, 
or clinical improvement and lgG- or IgM-containing CIC. 
The relative absence of IgG- or lgM-containing CIC in ow· 
patients, taken together with the variable results of previous 
investigators, suggest that lgG- or lgM-containing CIC do not 
play a primary role in psoriasis. The presence, however, of lgA-
containing CIC in the absence of IgG- or lgM-containing CIC 
suggests a relatively restricted pattern of immune reactivity. 
Since lgA is the immunoglobulin preferentially produced at the 
mucosal surface, it is possible that the existence of lgA-contain-
ing CIC is due to the presence of an abnormality of the gas-
trointestinal mucosa that has been reported in some patients 
with psoriasis [15,16]. At the present time, however, this re-
mains only an attractive hypothesis. The lack of conelation of 
IgA-containing CIC with clinical improvement in our patients 
suggests that, regardless of their origin, they are probably not 
directly related to the cutaneous manifestations of psoriasis. 
Recently, however, a number of observations have been made 
which suggest possible roles that lgA-containing CIC could play 
in the pathogenesis of psoriasis. 
It has been reported that receptors for the Fe portion of lgA 
are present both on human lymphocytes [17,18] and neutrophils 
(19,20]. In addition, Van Epps and coworkers have demon-
strated that polymeric lgA paraproteins can inhibit neutrophil 
chemotaxis and neutrophil bactericidal activity in vitro [21, 
22]. Since IgG-containing CIC are capable of modulating the 
function of lymphocytes and neutrophils, via the Fe receptors 
for IgG [23], it is also possible that a similar interaction between 
IgA-containing CIC and the Fe lgA receptors present on neu-
trophils and lymphocytes might be partially responsible for 
some of the abnormalities of neutrophil and lymphocyte func-
tion seen in patients with psoriasis. 
Several recent observations in psoriasis patients have been 
reported which make the possible interaction between IgA- . 
containing CIC and cell surface receptors even more intriguing. 
Sedgwick and coworkers have recently reported that neutro-
phils from patients with psoriasis are significantly more adher-
ent to nylon fiber columns than normal neutrophils, and that 
this increased adherence correlated positively with disease ac-
tivity [24]. While the cause of this defect is not known, the 
presence of activated complement components on the surface 
of the neutrophils has previously been reported to cause similar 
increased adherence [25]. lgA-containing CIC that have fixed 
complement, if bound to the smface of the neutrophil via an Fe 
IgA or C3b receptor, would provide such complement compo-
nents. In addition, Schroder et al also have recently reported 
the presence of a serum fraction in patients with psoriasis that 
has aM,. of 200,000 (within the 9S to 13S range) , is associated 
with the presence of lgA, and is able to inhibit neutrophil 
chemotaxis in vitro [26). It is not cleaT that this serum fraction 
contains lgA-containing CIC, but the similarities in sedimen-
tation characteristics suggest that lgA-containing CIC could be 
found in this serum fraction. 
In addition to these abnormalities in neutrophil function, 
functional T-cell defects have been noted to be present in some 
patients with psoriasis. The documentation of an Fe lgA recep-
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tor on human lymphocytes, suggests an additional possible role 
for lgA-containing CIC in modulation of the function of these 
lymphocytes. 
While the exact role of the lgA-containing CIC found in 
patients with psoriasis is not known, these recent observations 
suggest that although lgA-containing CIC do not appear to play 
a primary role in the pathogenesis of psoriasis they may be 
important in the modulation of the immune and inflammatory 
response in patients with this disease. 
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